Published in Biol Blood Marrow Transplant on November 20, 2014
Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biol Blood Marrow Transplant (2016) 0.78
Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplant (2016) 0.75
Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. Crit Rev Oncol Hematol (2015) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18
Graft-versus-host disease. Lancet (2009) 8.78
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr (2006) 6.60
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr (2009) 6.54
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2011) 6.36
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30
Statins as a newly recognized type of immunomodulator. Nat Med (2000) 5.00
Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation (2009) 4.62
Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 4.39
Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation (2006) 4.35
LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell (2008) 4.02
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med (2001) 3.69
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther (2006) 2.83
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol (2006) 2.70
Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation (2004) 2.49
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2008) 2.20
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood (2007) 2.19
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 2.11
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. J Clin Oncol (2013) 2.07
Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol (2008) 2.01
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis (2007) 1.87
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol (2010) 1.84
Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem (2007) 1.72
Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood (2007) 1.67
Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol (2013) 1.66
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol (2005) 1.65
Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med (2011) 1.61
Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat Immunol (2013) 1.61
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res (2002) 1.56
Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood (2002) 1.55
Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med (2001) 1.51
Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant (2007) 1.47
Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin Proc (1994) 1.47
Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA (1989) 1.40
Drug-induced liver injury associated with statins. Semin Liver Dis (2009) 1.36
Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant (2010) 1.33
Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med (2011) 1.23
Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant (2008) 1.20
Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology (1992) 1.19
Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood (2009) 1.19
Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant (2000) 1.14
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis (2004) 1.13
Effector T cells require fatty acid metabolism during murine graft-versus-host disease. Blood (2013) 1.13
mTORC1 inhibition via rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes. Lipids (2010) 1.07
Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs. Metabolism (2006) 1.05
Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant (2001) 1.04
Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2010) 0.99
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol (2009) 0.99
No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol (2001) 0.99
Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation (2001) 0.98
Hypothyroidism and dyslipidemia: modern concepts and approaches. Curr Cardiol Rep (2004) 0.98
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab (2011) 0.97
A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation (2005) 0.96
Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids. Eur J Clin Invest (1980) 0.95
Long-term physiological side effects after allogeneic bone marrow transplantation. Hematology Am Soc Hematol Educ Program (2010) 0.92
Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am (2007) 0.91
Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics (2008) 0.91
Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant (2009) 0.90
Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2011) 0.90
Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb (2012) 0.87
Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol (2011) 0.87
Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. Drugs (2010) 0.85
The emerging link between hypogonadism and metabolic syndrome. J Androl (2008) 0.85
Fatty acid-derived lipid mediators and blood platelet aggregation. Prostaglandins Leukot Essent Fatty Acids (2010) 0.84
Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. J Hepatol (1993) 0.83
Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis. Clin Transplant (2012) 0.83
Cardiovascular metabolic syndrome: mediators involved in the pathophysiology from obesity to coronary heart disease. Biomark Med (2012) 0.82
Elevated serum creatinine levels associated with fenofibrate therapy. Am J Health Syst Pharm (2008) 0.81
Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol (2007) 0.81
Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids. Curr Atheroscler Rep (2009) 0.80
Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant (2013) 0.80
Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant (2005) 0.77
Long-term lipid metabolism in combined kidney-pancreas transplant recipients under tacrolimus immunosuppression. Transplant Proc (2001) 0.76
Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation. Int J Hematol (2005) 0.76
Ursodiol: a cholesterol gallstone solubilizing agent. Drug Intell Clin Pharm (1988) 0.76
Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trial. Atherosclerosis (2008) 0.76
Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2009) 0.76
Studies on the mechanism of the ursodeoxycholic acid-induced increase in hepatic low-density lipoprotein binding. Lipids (1995) 0.75